Industry Background:
A drug-eluting balloon (DEB) is a semi-compliant angioplasty balloon, coated with anti-proliferative medicine. The medicine is ejected to the vessel walls during the inflation of the balloon. The balloons are inflated through the application of nominal pressure. The active substance of the balloon is highly lipophilic in nature. A drug-eluting balloon homogeneously delivers the drug to the vessel and prevents neointimal hyperplasia. The device has gained popularity as it helps the ineffective treatment of in-stent restenosis as compared to the drug-eluting stent or bare-metal stent. The rise in peripheral and coronary artery diseases among the geriatric population is likely to drive the global drug-eluting balloon market in the forecast period.This growth is primarily driven by Significantly Rising Vascular Disease Incidences
.
Attributes | Details |
---|
Study Period | 2018-2028 |
Base Year | 2022 |
Forecast Period | 2023-2028 |
Volume Unit | K Units |
Value Unit | USD (Million) |
Customization Scope | Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility |
The Pharmaceuticals sector in the
region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Medtronic Plc (United States), Boston Scientific Corporation (United States), Becton, Dickson and Company (United States), Terumo Corporation (Japan), Koninklijke Philips N.V. (Netherlands), Cook Group Incorporated (United States), Biotronik (Germany), Braun Melsungen AG (Germany), SurModics, Inc. (United States) and C.R. Bard (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
Key Developments in the Market:
In July , 2021 Medtronic plc . the global leader in medical technology, today announced the launch of the Prevail™ drug coated balloon (DCB) Catheter in Europe following CE mark. The newest coronary DCB on the market, the Prevail DCB is used during percutaneous coronary intervention (PCI) procedures to treat narrowed or blocked coronary arteries in patients with coronary artery disease (CAD).
Oct. 25, 2023 Boston Scientific Corporation announced positive 12-month results from the pivotal AGENT IDE clinical trial of the AGENT™ Drug-Coated Balloon (DCB).1 Primary endpoint findings from this first clinical trial in the U.S. to evaluate the safety and effectiveness of using a DCB to treat coronary in-stent restenosis (ISR) were presented in a late-breaking clinical trial session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation.Drug Eluting Balloon Reasearch in drug eluting ballon catheter space to key players anticipated bolster development and sales.
Influencing Trend:
Growing Demand for DCB Therapy
Market Growth Drivers:
Significantly Rising Vascular Disease Incidences, Growing Prevalence of Peripheral and Coronary Artery Diseases and Rising Geriatric Population across the Globe
Challenges:
Stringent Regulations For Approval
Restraints:
High Cost of Procedures and Products
Opportunities:
Rising Use of Drug-eluting Balloons Over Drug-Eluting Stents
AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.
Data Sources of Drug Eluting Balloon Market Study
Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Drug Eluting Balloon Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.
The primary interviews and data collected as per the below protocols: By Designation: C-Level, D-Level, Others
By Company Type: Tier 1, Tier 2, Tier 3
Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Drug Eluting Balloon players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.
Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
Against this Challenging Backdrop, Drug Eluting Balloon Study Sheds Light on
The Drug Eluting Balloon Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Drug Eluting Balloon industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Drug Eluting Balloon industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.